Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Radiant Biotherapeutics

Request full access

A biotechnology company developing the next generation of multi-specificity

Toronto, CanadaFounded 2020Biotech & Life Sciences

About Radiant Biotherapeutics

Radiant Biotherapeutics is a preclinical biotechnology firm established in 2020, with operations in Toronto and Philadelphia. The company is built upon foundational scientific research from The Hospital for Sick Children (SickKids) and the University of Toronto, specifically from the laboratories of Dr. Jean-Philippe Julien and Dr. Bebhinn Treanor. Venture capital firm Amplitude Ventures created the company, leading an initial $8 million seed round in 2023 along with partners including SickKids, Alexandria Investments, FACIT, and Toronto Innovation Acceleration Partners (TIAP). This was followed by a significant $35 million Series A financing in September 2024, co-led by the Bill & Melinda Gates Foundation and Amplitude Ventures, bringing the company's total funding to $43 million.

The core of Radiant's operations is its proprietary Multabody™ platform, which engineers multi-valent and multi-specific antibodies. This technology addresses limitations of current antibody therapies by combining superior binding strength, known as avidity, with the ability to target multiple disease-modifying proteins or different sites on the same target simultaneously. The platform uses a modular, fully human scaffold that allows for the rapid development of mono-, bi-, and tri-specific biologics, moving from concept to in vivo proof of concept in as little as six months. This efficiency is paired with the ability to leverage standard antibody manufacturing processes, simplifying production.

Radiant's business model is focused on developing a pipeline of therapeutic candidates and engaging in strategic research collaborations with pharmaceutical partners. The company is initially targeting oncology, inflammation, immunology, and infectious diseases such as HIV, supported by a grant from the Bill & Melinda Gates Foundation. Its lead clinical candidate, 4-1BB, is being advanced toward clinical trials for applications in oncology. Revenue generation is anticipated through the progression of its internal pipeline and validated by two existing, undisclosed partnerships with global pharmaceutical companies.

The company's leadership team includes President and CEO Deborah Geraghty, a life sciences executive with over two decades of experience in the biopharmaceutical industry. The scientific foundation is guided by co-founder Dr. Jean-Philippe Julien, who serves as Chair of the Scientific Advisory Board, and founding Chief Scientific Officer, Jo Hulme. The Multabody™ platform's potential was highlighted in its ability to neutralize SARS-CoV-2 and its variants with exceptional potency, demonstrating its versatility in addressing complex and rapidly mutating diseases.

Source: Dealroom company data

At a glance

Status
Operational
Employees
31
Open positions
None listed
Dealroom signal
52.7/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

5 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES A✓Equity / VC Sep 2024 $35M $140M Bill & Melinda Gates Foundation · Amplitude Ventures ↗
GRANT✓Other financing Dec 2023 $2M — Bill & Melinda Gates Foundation ↗
Showing the latest 2 of 5 recorded eventsBook a demo for the full funding history →

Growth signals

Radiant Biotherapeutics website traffic

Latest recorded traffic for Radiant Biotherapeutics is 610 monthly website visits, up 29.8% over the last three months. Radiant Biotherapeutics's team grew 0% over the past year.

Latest monthly visits610 3-month web change+29.8% 1-year team growth0%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Radiant Biotherapeutics in the Toronto ecosystem

Live from Dealroom

The Radiant Biotherapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

6 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed5 investors entered at this stage

  • Amplitude Ventures
  • Alexandria Venture Investments
  • FACIT (Fight Against Cancer Innovation Trust)
  • SickKids Centre for Global Child Health
  • Bill & Melinda Gates Foundation

Other known investors1 additional known investor

  • University of Toronto
Team profiled 2 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
2 countries with
team presence
🇨🇦 Canada79.3%
🇺🇸 United States20.7%
2 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Radiant Biotherapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Radiant Biotherapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.